NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00005036,Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT00005036,,COMPLETED,Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for colorectal cancer.,NO,Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,DRUG: irinotecan hydrochloride|DRUG: oxaliplatin|DRUG: leucovorin calcium|DRUG: fluorouracil|PROCEDURE: quality-of-life assessment,"Overall survival, The primary analysis for this trial will be based on a one-sided Generalized Wilcoxon test., At least 6 months","Time-to-tumor progression, Time from start of therapy to documentation of disease progression, assessed up to 3 years|Time-to-treatment failure, Time from the date of randomization to the date at which the patient is removed from treatment due to progression, toxicity, refusal, or death, assessed up to 3 years|Objective tumor response rate (CR or PR) in patients with measureable disease, At least 4 weeks|Toxicity and dose intensity, Up to 3 years|Quality of life, Up to 3 years",,National Cancer Institute (NCI),SWOG Cancer Research Network|Eastern Cooperative Oncology Group,ALL,"ADULT, OLDER_ADULT",PHASE3,560,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,NCI-2012-01847|N9841|SWOG-N9841|NCCTG-N9841|CDR0000067623|ECOG-N9841|U10CA025224,1999-11,2006-12,,2003-01-27,,2013-05-03,"North Central Cancer Treatment Group, Rochester, Minnesota, 55905, United States",
